Edition:
United States

Ardelyx Inc (ARDX.OQ)

ARDX.OQ on NASDAQ Stock Exchange Global Market

5.80USD
16 Feb 2018
Change (% chg)

$-0.20 (-3.33%)
Prev Close
$6.00
Open
$6.00
Day's High
$6.10
Day's Low
$5.70
Volume
72,405
Avg. Vol
143,596
52-wk High
$15.40
52-wk Low
$4.05

Select another date:

Mon, Jan 8 2018

BRIEF-Ardelyx Says Co Had About $134 Million In Cash

* ARDELYX SAYS ON JAN 8, CO HAD ABOUT $134 MILLION IN CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS AS OF DEC 31, 2017 Source text: (http://bit.ly/2AETXHu) Further company coverage:

BRIEF-Ardelyx Successfully Completes T3mpo-3 Safety Extension Study Of Tenapanor For Ibs-C

* ARDELYX SUCCESSFULLY COMPLETES T3MPO-3 SAFETY EXTENSION STUDY OF TENAPANOR FOR IBS-C

BRIEF-Ardelyx announces license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co for Tenapanor in China

* Ardelyx announces license agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited for Tenapanor in China

BRIEF-Ardelyx Inc says has decided to discontinue development of RDX7675 for treatment of hyperkalemia​​

* Ardelyx announces updated development path for its cardiorenal pipeline

BRIEF-Ardelyx qtrly ‍net loss per common share $0.44​

* Ardelyx reports third quarter 2017 operating results and clinical progress

BRIEF-Rock Springs Capital Management reports 5.02 pct passive stake in Ardelyx - SEC Filing

* Rock Springs Capital Management LP​ reports 5.02 percent passive stake in Ardelyx Inc as of Oct 23 - SEC filing Source text : (http://bit.ly/2gXpxsM) Further company coverage:

Ardelyx's constipation drug succeeds in late-stage trial

Ardelyx Inc said a second late-stage trial of its drug for irritable bowel syndrome with constipation (IBS-C) met the main goal of reducing abdominal pain and increasing bowel movement, sending its shares up sharply in extended trading.

BRIEF-Ardelyx's Phase 3 study of Tenapanor for IBS-C hits primary and secondary endpoints

* Ardelyx's pivotal Phase 3 study of Tenapanor for IBS-C hits primary and all secondary endpoints to support NDA submission in 2018

Ardelyx's irritable bowel syndrome drug succeeds in trial

Oct 11 Ardelyx Inc said on Wednesday a second late-stage trial of its experimental drug for irritable bowel syndrome with constipation (IBS-C) met the main goal of reducing abdominal pain and increasing bowel movements.

BRIEF-Deerfield Management reports a 5.79 pct passive stake in Ardelyx‍​

* Deerfield Management LP reports a 5.79 pct passive stake in Ardelyx Inc as of August 21 - SEC filing ‍​ Source text: (http://bit.ly/2vMywBL) Further company coverage:

Select another date: